TY - JOUR AU - Debeij, J. AU - Dekkers, O. M. AU - Asvold, B. O. AU - Christiansen, S. C. AU - Naess, I. A. AU - Hammerstrom, J. AU - Rosendaal, F. R. AU - Cannegieter, S. C. PY - 2012 DA - 2012// TI - Increased levels of free thyroxine and risk of venous thrombosis in a large population-based prospective study T2 - J Thromb Haemost JO - Journal of Thrombosis and Haemostasis : JTH SP - 1539 EP - 1546 VL - 10 IS - 8 KW - Adult KW - Aged KW - 80 and over KW - Autoantibodies/blood KW - Biological Markers/blood KW - Case-Control Studies KW - Female KW - Humans KW - Logistic Models KW - Male KW - Middle Aged KW - Norway/epidemiology KW - Odds Ratio KW - Prospective Studies KW - Risk Assessment KW - Risk Factors KW - Thyrotropin/blood KW - Thyroxine/*blood KW - Time Factors KW - Up-Regulation KW - Venous Thrombosis/*blood/epidemiology AB - BACKGROUND: Recent studies have shown that high levels of free thyroxine (FT4), even without leading to hyperthyroidism, are associated with a procoagulant state. OBJECTIVES: The aim of our study was to determine whether high levels of thyroid hormones are associated with an increased risk of venous thrombosis. PATIENTS/METHODS: From a prospective nested case-cohort design within the second Nord-Trondelag Health Study (HUNT2) cohort (1995-1997; 66,140 subjects), all patients with venous thrombosis during follow-up (n=515) and 1476 randomly selected age-stratified and sex-stratified controls were included. Relative and absolute risks for venous thrombosis were calculated for different cut-off levels of thyroid hormones on the basis of percentiles in the controls and different times between blood sampling and thombosis. RESULTS: In subjects with an FT4 level above the 98th percentile (17.3 pmol L(-1)), the odds ratio (OR) was 2.5 (95% confidence interval [CI] 1.3-5.0) as compared with subjects with levels below this percentile. For venous thrombosis within 1 year from blood sampling, this relative risk was more pronounced, with an OR of 4.8 (95% CI 1.7-14.0). Within 0.5 years, the association was even stronger, with an OR of 9.9 (95% CI 2.9-34.0, adjusted for age, sex, and body mass index). For thyroid-stimulating hormone, the relationship was inverse and less pronounced. The absolute risk within 6 months in the population for FT4 levels above the 98th percentile was 6.1 per 1000 person-years (95% CI 1.7-15.7). CONCLUSIONS: Levels of FT4 at the upper end of the normal range are a strong risk factor for venous thrombosis. The risk increased with higher levels of thyroxine and shorter time between blood sampling and thrombosis. Further studies on the effect of clinical hyperthyroidism are warranted. SN - 1538-7836 UR - http://www.ncbi.nlm.nih.gov/pubmed/22703181 UR - https://doi.org/10.1111/j.1538-7836.2012.04818.x DO - 10.1111/j.1538-7836.2012.04818.x LA - English N1 - PMID:22703181 ID - Debeij_etal2012 ER -